ERBB2 and neoplasm: Prognostic biomarkers-such as RAS, BRAF, HER2 alterations, mismatch repair deficiency, tumor mutational burden, methylation signatures, and non-coding RNAs-provide insight into tumor behavior and recurrence risk.